Cargando…

The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells

β-Galactosylceramidase (GALC) is a lysosomal enzyme involved in sphingolipid metabolism by removing β-galactosyl moieties from β-galactosylceramide and β-galactosylsphingosine. Previous observations have shown that GALC may exert pro-oncogenic functions in melanoma and Galc silencing, leading to dec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capoferri, Davide, Chiodelli, Paola, Corli, Marzia, Belleri, Mirella, Scalvini, Elisa, Mignani, Luca, Guerra, Jessica, Grillo, Elisabetta, De Giorgis, Veronica, Manfredi, Marcello, Presta, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342161/ https://www.ncbi.nlm.nih.gov/pubmed/37445731 http://dx.doi.org/10.3390/ijms241310555

Ejemplares similares

β-Galactosylceramidase in cancer: more than a psychosine scavenger
por: Belleri, Mirella, et al.
Publicado: (2022)

β-Galactosylceramidase Deficiency Causes Bone Marrow Vascular Defects in an Animal Model of Krabbe Disease
por: Belleri, Mirella, et al.
Publicado: (2019)

Zebra-Sphinx: Modeling Sphingolipidoses in Zebrafish
por: Mignani, Luca, et al.
Publicado: (2023)

β-Galactosylceramidase Deficiency Causes Upregulation of Long Pentraxin-3 in the Central Nervous System of Krabbe Patients and Twitcher Mice
por: Coltrini, Daniela, et al.
Publicado: (2022)

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity
por: Simpson, Dennis A., et al.
Publicado: (2015)

Quantification of 3D Brain Microangioarchitectures in an Animal Model of Krabbe Disease
por: Righi, Marco, et al.
Publicado: (2019)

Reliable and Fast Genotyping Protocol for Galactosylceramidase (Galc) in the Twitcher (Twi) Mouse
por: Carpi, Sara, et al.
Publicado: (2022)

GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease
por: Senkevich, Konstantin, et al.
Publicado: (2022)

Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease
por: Iacono, Diego, et al.
Publicado: (2022)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Brainstem development requires galactosylceramidase and is critical for pathogenesis in a model of Krabbe disease
por: Weinstock, Nadav I., et al.
Publicado: (2020)

Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration
por: Kreher, Conlan, et al.
Publicado: (2022)

Lysosomal TMEM106B interacts with galactosylceramidase to regulate myelin lipid metabolism
por: Takahashi, Hideyuki, et al.
Publicado: (2023)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

In vitro Validation of Chimeric β-Galactosylceramidase Enzymes With Improved Enzymatic Activity and Increased Secretion
por: Ricca, Alessandra, et al.
Publicado: (2020)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Long-Pentraxin 3 Affects Primary Cilium in Zebrafish Embryo and Cancer Cells via the FGF System
por: Guerra, Jessica, et al.
Publicado: (2020)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Re-Configuration of Sphingolipid Metabolism by Oncogenic Transformation
por: Don, Anthony S., et al.
Publicado: (2014)

Uncoupling of the LKB1-AMPKα Energy Sensor Pathway by Growth Factors and Oncogenic BRAF(V600E)
por: Esteve-Puig, Rosaura, et al.
Publicado: (2009)

Cross-Regulation between Oncogenic BRAF(V600E) Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma
por: Lee, Seong Jin, et al.
Publicado: (2011)

Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene
por: Hall, Arnaldur, et al.
Publicado: (2013)

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
por: Goodall, Megan L, et al.
Publicado: (2014)

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF(V600E) Protein
por: Marini, Elisabetta, et al.
Publicado: (2022)

Avian Reovirus P17 Suppresses Angiogenesis by Promoting DPP4 Secretion
por: Manocha, Ekta, et al.
Publicado: (2021)

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
por: Kumar, Raj, et al.
Publicado: (2019)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression
por: Śmiech, Magdalena, et al.
Publicado: (2022)

Development of a potent small‐molecule degrader against oncogenic BRAF(V600E) protein that evades paradoxical MAPK activation
por: Ohoka, Nobumichi, et al.
Publicado: (2022)

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

BRAF V600E-Negative Hairy Cell Leukaemia
por: Langabeer, Stephen E., et al.
Publicado: (2013)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5viojinen7ueeaoicviuu4ikfl